1. Home
  2. CRI vs LQDA Comparison

CRI vs LQDA Comparison

Compare CRI & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRI
  • LQDA
  • Stock Information
  • Founded
  • CRI 1865
  • LQDA 2004
  • Country
  • CRI United States
  • LQDA United States
  • Employees
  • CRI N/A
  • LQDA N/A
  • Industry
  • CRI Apparel
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRI Consumer Discretionary
  • LQDA Health Care
  • Exchange
  • CRI Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • CRI 1.3B
  • LQDA 1.4B
  • IPO Year
  • CRI 2003
  • LQDA 2018
  • Fundamental
  • Price
  • CRI $31.36
  • LQDA $14.92
  • Analyst Decision
  • CRI Sell
  • LQDA Strong Buy
  • Analyst Count
  • CRI 5
  • LQDA 8
  • Target Price
  • CRI $36.80
  • LQDA $27.13
  • AVG Volume (30 Days)
  • CRI 1.6M
  • LQDA 2.1M
  • Earning Date
  • CRI 07-25-2025
  • LQDA 05-08-2025
  • Dividend Yield
  • CRI 8.45%
  • LQDA N/A
  • EPS Growth
  • CRI N/A
  • LQDA N/A
  • EPS
  • CRI 4.51
  • LQDA N/A
  • Revenue
  • CRI $2,812,437,000.00
  • LQDA $14,144,000.00
  • Revenue This Year
  • CRI N/A
  • LQDA $224.65
  • Revenue Next Year
  • CRI N/A
  • LQDA $250.54
  • P/E Ratio
  • CRI $6.95
  • LQDA N/A
  • Revenue Growth
  • CRI N/A
  • LQDA N/A
  • 52 Week Low
  • CRI $31.07
  • LQDA $8.26
  • 52 Week High
  • CRI $71.99
  • LQDA $19.41
  • Technical
  • Relative Strength Index (RSI)
  • CRI 39.01
  • LQDA 45.94
  • Support Level
  • CRI $31.07
  • LQDA $13.94
  • Resistance Level
  • CRI $33.97
  • LQDA $17.88
  • Average True Range (ATR)
  • CRI 1.49
  • LQDA 1.40
  • MACD
  • CRI -0.19
  • LQDA -0.33
  • Stochastic Oscillator
  • CRI 3.89
  • LQDA 17.92

About CRI Carter's Inc.

Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: